Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a biotechnology company focused on developing novel cancer treatments, stands at ...

Akero Therapeutics’ impressive performance in both stock price and clinical trials has made it a stock to watch in 2025. With a promising treatment on the horizon and significant gains to show for it, ...

In a challenging market environment, Centrexion Therapeutics Corp stock has touched a 52-week low, with shares falling to $0.9. According to InvestingPro data, the stock shows significant volatility ...

These two Fate series are a great way to pass the time until an official release date drops for the first season of ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.

Context Therapeutics (CNTX) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6, or ...

CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context ...

PHILADELPHIA - Context Therapeutics Inc. (NASDAQ:CNTX), a company specializing in T cell engaging therapies for solid tumors, announced today the appointment of Andy Pasternak as its new Chairman of ...

PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today ...